Abstract
We describe the dynamics of the vaccine-specific antibody response in the breastmilk and serum in a prospective cohort of ten lactating women who received two doses of the Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine. The antibody response was rapid and highly synchronized between breastmilk and serum, reaching stabilization 14 days after the second dose. The predominant serum antibody was IgG. The response in the breastmilk included both IgG and IgA with neutralizing capacity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Israeli Ministry of Health (MOH) grant #3-0000-17162)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Sample collection was performed under the following ethical approvals: 1/ Institutional review board (IRB) approvals number 0002269-4 and 0002757-1 given at Tel Aviv University. Chair of IRB committee Prof. Meir Lahav, Faculty Medicine, Tel Aviv University. 2/ Ethical approval number 1088-20-TLV given at Tel Aviv Sourasky medical center. Prof. Shmuel Kivity, Chairman, Institutional Review Board (IRB) / Ethics (Helsinki) Committee,Tel Aviv Sourasky medical center and under approval by the director of Tel Aviv Sourasky medical center, Prof. Ronni Gamzu. All participants provided informed consent for the use of their data and clinical samples for the purposes of the present study. Study participant's data includes less than three indirect identifiers throughout the manuscript in compliance with ethical guidelines.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available on request due to privacy or other restrictions
